1. Home
  2. LEXX

as 12-20-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

;SMA (50)$2.38EMA (200)$2.65O: $2.22 H: $2.23 L: $2.15 C: $2.23 +0.01 (+0.45%)Elder Ray −0.06, −0.14
Founded: 2004 Country:
Canada
Canada
Employees: N/A City: KELOWNA
Market Cap: 38.9M IPO Year: N/A
Target Price: $11.00 AVG Volume (30 days): 202.7K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.47 EPS Growth: N/A
52 Week Low/High: $1.20 - $6.85 Next Earning Date: 01-10-2025
Revenue: $464,278 Revenue Growth: 105.24%
Revenue Growth (this year): 20.39% Revenue Growth (next year): 113.25%

LEXX Daily Stock ML Predictions

SELLHOLDBUYas of 2 days ago

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use